Sequenom, a life sciences company, has appointed Paul V. Maier as interim chief financial officer (CFO), reporting directly to the company’s interim chief executive officer (CEO) and chairman of the board, Harry Hixson, Jr.
Maier has been an independent financial consultant since February 2007. He served as senior vice president and CFO of Ligand Pharmaceuticals from 1992 until January 2007, where he helped build Ligand from a venture stage boutique company to a commercial, integrated biopharmaceutical organisation. During his tenure at Ligand, Maier helped to raise over US$1bn in equity and debt financings. Prior to Ligand, Maier spent six years in various management and finance positions at ICN Pharmaceuticals.
The annual BNP Paribas Cash Management University kicked off on Thursday morning with treasury professionals congregating in Paris from across Europe.
APIs may be a solution to MT940 challenges, says Karen Fagan, treasury operation manager, for British television company, ITV.
Kicking off the first day of the Singapore Fintech Festival, issues with cryptocurrencies were addressed by MIT media labs director, Joi Ito, and panels of technology leaders discussed how they’re using data analytics.
Sibos 2017 day two highlights: Brexit and banking, and why ‘data is the new oil’ in financial services
How nation first politics can impact global financial organisations It’s clear that data and regulation are the two key topics that are ... read more